Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022

EconomyOct 28, 2021 15:59
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo

By Michael Erman and Manas Mishra

(Reuters) -Merck & Co Inc on Thursday said its experimental COVID-19 drug could bring in between $5 billion and $7 billion in sales through the end of next year, assuming it gains U.S. authorization in December.

Merck's shares rose more than 4% to $84.88 in early trading.

The antiviral drug, molnupiravir, has been closely watched since Merck earlier this month reported data https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01 that showed it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19 when given early in the illness.

U.S. Food and Drug Administration advisers will meet in November to vote on whether the drug should be authorized. If cleared by the FDA, the medicine developed with Ridgeback Biotherapeutics will become the first oral antiviral treatment for COVID-19.

Merck Chief Executive Robert Davis said in an interview the $5 billion to $7 billion forecast for the pill is based on signed contracts and regions where the company has high confidence that they will reach a deal, and that the estimate could move higher.

"We will have more courses available than what we have sales for right now," Davis said. He noted that demand could spike if the drug is found to also be effective in preventing COVID-19 after exposure to the virus.

"That upside is not in these numbers," he said.

While vaccines remain the main weapons against COVID-19, Merck's experimental pill could be a game-changer as other treatments for the disease are given as infusions or injections, primarily in a hospital setting. Molnupiravir is taken twice a day for five days.

Merck said it expects between $500 million and $1 billion in sales of the drug this year. Profits will be shared equally with Ridgeback.

The U.S. drugmaker in June agreed to provide 1.7 million doses of molnupiravir to the U.S. government for around $1.2 billion, once it is cleared by regulators. Other countries have rushed to sign deals for the drug since its data was announced.

Merck has also signed pacts https://www.reuters.com/business/healthcare-pharmaceuticals/merck-signs-pact-broaden-generic-manufacturing-covid-19-pill-2021-10-27/#:~:text=WASHINGTON%2C%20Oct%2027%20(Reuters),and%20the%20organization%20announced%20on with generic drugmakers to produce the drug for low- and middle-income countries.

It expects to produce 10 million courses of the drug this year, and sees that number more than doubling in 2022. Its production targets do not include the licensing deals for generic versions.

Also on Thursday, Merck raised its full-year adjusted profit forecast following strong third-quarter demand for blockbuster cancer drug Keytruda, and a 68% spike in sales of Gardasil, its vaccine to prevent cancers caused by the human papillomavirus.

Sales of Keytruda, which is on track to become the world's biggest-selling medicine by 2023, rose 22% to $4.53 billion in the quarter, topping analysts' lofty estimates of $4.31 billion.

Merck now expects full-year adjusted profit of $5.65 to $5.70 per share, up from its prior view of $5.47 to $5.57. The forecasts did not include any potential contribution from molnupiravir.

Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022
 

Related Articles

Glencore widens review of assets, eyes acquisitions
Glencore widens review of assets, eyes acquisitions By Reuters - Dec 02, 2021

By Clara Denina and Zandi Shabalala LONDON (Reuters) - Miner and trader Glencore (LON:GLEN) said on Thursday it was in the process of selling 10 more assets, putting another 15...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Drake Richards
Drake Richards Oct 28, 2021 16:34
Saved. See Saved Items.
This comment has already been saved in your Saved Items
and the ghost of Covid will keep rattling it's chains as long as there is money to be made out of it.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email